Original Research

DOI: 10.4244/EIJ-D-23-00838

Same-day discharge after large-bore access in percutaneous coronary intervention of chronic total coronary occlusions

Yvemarie B.O. Somsen1, MD; Adriaan Wilgenhof2,3, MD; Roel Hoek1, MD; Stefan P. Schumacher1, MD; Camila S. Pizarro Perez1, MD; Pepijn A. van Diemen1, MD; Ruurt A. Jukema1, MD; Wynand J. Stuijfzand1, MD, PhD; Jos W.R. Twisk4, PhD; Ibrahim Danad5, MD, PhD; Niels J. Verouden1, MD, PhD; Alexander Nap1, MD, PhD; Ruben W. de Winter1, MD; José P. Henriques6, MD, PhD; Paul Knaapen1, MD, PhD

Abstract

BACKGROUND: Same-day discharge (SDD) in patients undergoing percutaneous coronary intervention (PCI) of a chronic total occlusion (CTO) is appealing because of the increased patient comfort. However, data on SDD following large-bore vascular access are scarce.

AIMS: We investigated the feasibility and safety of SDD in patients undergoing large-bore CTO PCI.

METHODS: Between 2013 and 2023, 948 patients were prospectively enrolled in a single-centre CTO registry and underwent CTO PCI. SDD was pursued in all patients. Large-bore access was defined as the use of ≥7 French (Fr) sheaths in ≥1 access site. A logistic regression analysis was used to identify predictors for non-SDD. Clinical follow-up was obtained at 30 days.

RESULTS: SDD was observed in 62% of patients. Large-bore access was applied in 99% of the cohort. SDD patients were younger and more often male, with lower rates of renal insufficiency and prior coronary artery bypass grafting. Local access site bleeding (odds ratio [OR] 8.53, 95% confidence interval [CI]: 5.24-13.87) and vascular access complications (OR 7.23, 95% CI: 1.98-26.32) made hospitalisation more likely, with vascular access complications occurring in 3%. At 30 days, the hospital readmission rate was low in both SDD and non-SDD patients (5% vs 7%; p=non-significant). Finally, SDD was not a predictor for major adverse cardiovascular events (MACE) at follow-up.

CONCLUSIONS: Same-day discharge can be achieved in the majority of patients undergoing CTO PCI with large-bore (≥7 Fr) access. Similar low hospital readmission and MACE rates between SDD and non-SDD patients at 30 days demonstrate the feasibility and safety of SDD.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 10
May 20, 2024
Volume 20 Number 10
View full issue


Key metrics

Suggested by Cory

Clinical research

10.4244/EIJ-D-19-00441 Dec 4, 2020
Technical and procedural outcomes of the retrograde approach to chronic total occlusion interventions
Tajti P et al
free

10.4244/EIJV12I11A218 Dec 9, 2016
Conquering CTO revascularisation: the summit is near with 90% of the ascent behind us
Di Mario C and Dini C
free

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free

Expert review

10.4244/EIJ-D-18-00826 Jun 20, 2019
Percutaneous recanalisation of chronic total occlusions: 2019 consensus document from the EuroCTO Club
Galassi A et al
free

Research correspondence

10.4244/EIJ-D-22-00599 Dec 2, 2022
In-hospital outcomes and temporal trends of percutaneous coronary interventions for chronic total occlusion
Kostantinis S et al
free
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved